Anti-VEGF for submacular hemorrhage from AMD reduces lesions, improves vision

Anti-VEGF monotherapy improved visual and anatomic outcomes in the treatment of large sub-retinal hemorrhages attributed to neovascular age-related macular degeneration, according to a study.The retrospective study included 19 eyes of 18 patients with neovascular AMD and submacular hemorrhage who underwent anti-VEGF monotherapy. Mean patient age was 81 years.

Full Story →